SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization and global expansion of its SSi Mantra surgical robotic system. As of September 8, 2026, the company has recorded 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has also grown 42%, reaching 238 systems across 12 countries, up from 168 systems previously. This expansion underscores the company's progress in making robotic surgery more accessible worldwide.
The SSi Mantra platform has now been used for more than 170 types of surgical procedures, and approximately 1,500 physicians have been trained on the system. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its potential to address diverse surgical needs in different regions.
SS Innovations also emphasized its achievements in pediatric and telesurgery. As of August 31, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system's efficiency and reliability in high-volume settings.
Looking forward, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding into major markets and could significantly accelerate adoption of the SSi Mantra system.
The company's growth trajectory and international expansion are detailed in its full report, available at https://ibn.fm/DJILj. SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors and industry observers, the 79% growth in procedures and 42% increase in installed base demonstrate strong momentum. The upcoming FDA and CE marking decisions could open the door to the U.S. and European markets, potentially driving further adoption. The company's focus on affordability and accessibility positions it to compete in the growing surgical robotics market, where demand for minimally invasive options is rising. As SS Innovations continues to train physicians and expand its global footprint, its impact on surgical care could be substantial. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
